Developer docs
API playgroundTry for free, no card

Search company profiles

Proteins.1

Full company profile

uuid02c24rg

Namestring
Proteins.1
Legal namestring
Proteins1 Oy
Websiteurl
proteins1.com
Company typeenum
Private
Founded yearint
2026
Descriptiontext

Proteins.1 is a Helsinki-based Finnish deep-tech startup that spun out from VTT Technical Research Centre of Finland in April 2026 to commercialize a patented, physics-based, enzyme-free multiomics detection platform. The company's core technology enables ultra-sensitive single-molecule protein amplification, with stated detection sensitivity up to 1,000 times higher than current gold-standard methods, and is positioned as analogous to PCR but applied to proteins without enzymes. The platform works simultaneously for DNA, RNA, and proteins, allowing researchers to detect disease markers at lower abundance, accelerate drug discovery, and access previously invisible biology. Intellectual property is protected by granted US and Finnish patents with additional international patent applications pending.

The company's go-to-market is sales-led, initially targeting research-use-only applications in oncology, neurology, and immunology, with a stated plan to progress toward regulated clinical diagnostics in the global diagnostics market. Revenue mechanics are described as hardware sales of research-use-only products first, with future regulated clinical diagnostic hardware sales as the secondary stream; pricing is not publicly disclosed and no distribution channels are yet established. The company plans a direct sales model aimed at large research institutions and pharmaceutical companies.

Proteins.1 launched with €4.7 million in pre-seed funding co-led by Lifeline Ventures and Cloudberry Ventures, with in-kind support from VTT and Business Finland. It is led by three co-founders, Harri Hallila, Prateek Singh, and Tuan Nguyen, operates with 1-10 employees out of Helsinki, and plans to expand its engineering and product development team in Finland during 2026 and 2027. The company is pre-revenue and pre-commercial launch.

Short descriptiontext

Proteins.1 is a Helsinki-based Finnish deep-tech startup developing a physics-based, enzyme-free multiomics detection platform that enables ultra-sensitive single-molecule protein, DNA, and RNA analysis for life-sciences research and future clinical diagnostics.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersEspoo, Finland
HQ citystring
Espoo
HQ countrystring
Finland
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
multiomics detection platform, single-molecule protein analysis, enzyme-free proteomics, biomarker research instruments, ultra-sensitive protein detection
Industry2 codes
SECONDARYHLAGADAG
Proteomics & Biomarker Analytical Testing
SECONDARYHLAAALAL
Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays)
NAICS code3 codes
  • In-Vitro Diagnostic Substance Manufacturing325413
  • Analytical Laboratory Instrument Manufacturing334516
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Laboratory Analytical Instruments3826
Product category
Multiomics Detection Platforms
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Research-Use-Only Products
TypeHardware Sales
Description

Initial revenue stream from research-use-only applications in oncology, neurology, and immunology before advancing to regulated clinical diagnostics.

pulse2.com
2Clinical Diagnostics
TypeHardware Sales
Description

Future regulated clinical diagnostics targeting the global diagnostics market.

prnewswire.com
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Proteins.1 commercializes a physics-based, enzyme-free multiomics platform that enables ultra-sensitive single-molecule protein detection and simultaneous analysis of DNA, RNA, and proteins. The platform delivers up to 1,000 times higher detection sensitivity than current gold-standard methods, targeting research-use-only applications in oncology, neurology, and immunology with a future pathway into regulated clinical diagnostics.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Detection sensitivity up to 1,000 times higher than current gold-standard platforms
Product overview1 text field

Proteins.1 is a single unified product platform — an enzyme-free, physics-based multiomics detection platform that enables ultra-sensitive single-molecule protein amplification. The platform works simultaneously for DNA, RNA, and proteins, delivering detection sensitivity up to 1,000 times higher than current gold-standard methods. The company initially targets research-use-only applications in oncology, neurology, and immunology before progressing toward regulated clinical diagnostics in the global diagnostics market.

Product and service1 record
1Proteins.1 Platform
CategoryMultiomics Detection Platform
Description

Physics-based, enzyme-free multiomics detection platform enabling ultra-sensitive single-molecule protein detection with simultaneous analysis of DNA, RNA, and proteins. Provides detection sensitivity up to 1,000 times higher than current gold-standard methods, targeting early disease detection, biomarker research, and drug discovery applications in oncology, neurology, and immunology.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Parent organization from which Proteins.1 spun off. Provided in-kind support and originally developed the patented technology. VTT continues as a strategic partner for research and development.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Olink provides high-multiplex proximity extension assay-based proteomics platforms serving pharma and academic research customers in oncology, neurology, and immunology — directly overlapping Proteins.1's initial target use cases.

TypeDirect peer
Description

Quanterix commercializes ultra-sensitive single-molecule protein detection via its Simoa platform, the closest direct competitor to Proteins.1's core single-molecule protein amplification technology. Both target low-abundance biomarker discovery and clinical diagnostics.

TypeDirect peer
Description

SomaLogic offers SomaScan, a large-scale proteomics platform for biomarker discovery and disease research, serving pharma and clinical research customers in similar applications to Proteins.1.

TypeBroad incumbent
Description

10x Genomics offers single-cell multiomics platforms (Chromium, Visium) for simultaneous genomics and proteomics research. While its core is single-cell genomics, its multiomics roadmap overlaps Proteins.1's simultaneous DNA/RNA/protein vision.

TypeBroad incumbent
Description

Bio-Techne provides proteomics reagents, ELISA kits, and analytical tools (including the ProteinSimple branded Western blot and Simple Plex platforms) used in the same research workflows Proteins.1 aims to disrupt.

TypeEmerging player
Description

Quantum-Si is an early-stage company developing single-molecule protein sequencing using semiconductor chip technology — an alternative architectural approach to next-generation protein detection with similar ambitions to Proteins.1.

TypeBroad incumbent
Description

Abcam supplies antibodies and proteomics research tools widely used in protein detection workflows that Proteins.1's enzyme-free approach aims to bypass. Recently acquired by Danaher.

TypeBroad incumbent
Description

Illumina is the dominant sequencing platform vendor and increasingly active in proteomics-adjacent multiomics. Its installed base and clinical-diagnostics channel are relevant comparables for Proteins.1's regulated diagnostics ambitions.

TypeDirect peer
Description

Standard BioTools provides mass cytometry and microfluidic instrumentation for single-cell multiomics workflows. Its technologies overlap with Proteins.1's goal of single-molecule, multi-analyte detection.

TypeBroad incumbent
Description

Thermo Fisher's life-sciences instruments division supplies mass spectrometry, qPCR, and proteomics workflows used by the same research and clinical customers Proteins.1 targets. It also sells diagnostic instruments through its specialty diagnostics segment.

Market position
Strengths1 record

Each record includes

Headline, Details, Source

Weaknesses1 record

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Proteins.1

Multiomics Detection Platformsproteins1.com

Proteins.1 is a Helsinki-based Finnish deep-tech startup developing a physics-based, enzyme-free multiomics detection platform that enables ultra-sensitive single-molecule protein, DNA, and RNA analysis for life-sciences research and future clinical diagnostics.

What Proteins.1 does

Proteins.1 is a Helsinki-based Finnish deep-tech startup that spun out from VTT Technical Research Centre of Finland in April 2026 to commercialize a patented, physics-based, enzyme-free multiomics detection platform. The company's core technology enables ultra-sensitive single-molecule protein amplification, with stated detection sensitivity up to 1,000 times higher than current gold-standard methods, and is positioned as analogous to PCR but applied to proteins without enzymes. The platform works simultaneously for DNA, RNA, and proteins, allowing researchers to detect disease markers at lower abundance, accelerate drug discovery, and access previously invisible biology. Intellectual property is protected by granted US and Finnish patents with additional international patent applications pending.

The company's go-to-market is sales-led, initially targeting research-use-only applications in oncology, neurology, and immunology, with a stated plan to progress toward regulated clinical diagnostics in the global diagnostics market. Revenue mechanics are described as hardware sales of research-use-only products first, with future regulated clinical diagnostic hardware sales as the secondary stream; pricing is not publicly disclosed and no distribution channels are yet established. The company plans a direct sales model aimed at large research institutions and pharmaceutical companies.

Proteins.1 launched with €4.7 million in pre-seed funding co-led by Lifeline Ventures and Cloudberry Ventures, with in-kind support from VTT and Business Finland. It is led by three co-founders, Harri Hallila, Prateek Singh, and Tuan Nguyen, operates with 1-10 employees out of Helsinki, and plans to expand its engineering and product development team in Finland during 2026 and 2027. The company is pre-revenue and pre-commercial launch.

Proteins.1 firmographics

Firmographics
Name
Proteins.1
Legal name
Proteins1 Oy
Website
https://proteins1.com
Company type
Private
Founded year
2026
Operating status
Operating
Headcount range
1–10 employees
Short description
Proteins.1 is a Helsinki-based Finnish deep-tech startup developing a physics-based, enzyme-free multiomics detection platform that enables ultra-sensitive single-molecule protein, DNA, and RNA analysis for life-sciences research and future clinical diagnostics.
Ownership category
akta.pro rank

Where Proteins.1 is headquartered

Location

Headquarters

HQ city
Espoo
HQ country
Finland
HQ region
Europe

Offices1 record

Markets served

Proteins.1 business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

  1. Research-Use-Only Products: Initial revenue stream from research-use-only applications in oncology, neurology, and immunology before advancing to regulated clinical diagnostics.
  2. Clinical Diagnostics: Future regulated clinical diagnostics targeting the global diagnostics market.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Proteins.1 product offering

Product offering

Core offering

Proteins.1 commercializes a physics-based, enzyme-free multiomics platform that enables ultra-sensitive single-molecule protein detection and simultaneous analysis of DNA, RNA, and proteins. The platform delivers up to 1,000 times higher detection sensitivity than current gold-standard methods, targeting research-use-only applications in oncology, neurology, and immunology with a future pathway into regulated clinical diagnostics.

Product overview

Proteins.1 is a single unified product platform — an enzyme-free, physics-based multiomics detection platform that enables ultra-sensitive single-molecule protein amplification. The platform works simultaneously for DNA, RNA, and proteins, delivering detection sensitivity up to 1,000 times higher than current gold-standard methods. The company initially targets research-use-only applications in oncology, neurology, and immunology before progressing toward regulated clinical diagnostics in the global diagnostics market.

Differentiator

Problem solved

Functional benefit

Products and services

  • Proteins.1 Platform Physics-based, enzyme-free multiomics detection platform enabling ultra-sensitive single-molecule protein detection with simultaneous analysis of DNA, RNA, and proteins. Provides detection sensitivity up to 1,000 times higher than current gold-standard methods, targeting early disease detection, biomarker research, and drug discovery applications in oncology, neurology, and immunology.

Quantifiable outcome

  • Detection sensitivity up to 1,000 times higher than current gold-standard platforms

Companies that use Proteins.1

Customer profile

Segments2 records

Ideal customer profiles2 records

Proteins.1 technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature1 record

Proteins.1 partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • VTT Technical Research Centre of FinlandcoreStrategic or Co-development PartnerParent organization from which Proteins.1 spun off. Provided in-kind support and originally developed the patented technology. VTT continues as a strategic partner for research and development.

Scale indicators3 records

Recent moves8 records

Expansion highlights5 records

Proteins.1 competitors and assessment

Company assessment

Direct peers

  • Olink Holding: Olink provides high-multiplex proximity extension assay-based proteomics platforms serving pharma and academic research customers in oncology, neurology, and immunology — directly overlapping Proteins.1's initial target use cases.
  • Quanterix: Quanterix commercializes ultra-sensitive single-molecule protein detection via its Simoa platform, the closest direct competitor to Proteins.1's core single-molecule protein amplification technology. Both target low-abundance biomarker discovery and clinical diagnostics.
  • SomaLogic: SomaLogic offers SomaScan, a large-scale proteomics platform for biomarker discovery and disease research, serving pharma and clinical research customers in similar applications to Proteins.1.
  • Standard BioTools (formerly Fluidigm): Standard BioTools provides mass cytometry and microfluidic instrumentation for single-cell multiomics workflows. Its technologies overlap with Proteins.1's goal of single-molecule, multi-analyte detection.

Broad incumbents

  • 10x Genomics: 10x Genomics offers single-cell multiomics platforms (Chromium, Visium) for simultaneous genomics and proteomics research. While its core is single-cell genomics, its multiomics roadmap overlaps Proteins.1's simultaneous DNA/RNA/protein vision.
  • Bio-Techne: Bio-Techne provides proteomics reagents, ELISA kits, and analytical tools (including the ProteinSimple branded Western blot and Simple Plex platforms) used in the same research workflows Proteins.1 aims to disrupt.
  • Abcam: Abcam supplies antibodies and proteomics research tools widely used in protein detection workflows that Proteins.1's enzyme-free approach aims to bypass. Recently acquired by Danaher.
  • Illumina: Illumina is the dominant sequencing platform vendor and increasingly active in proteomics-adjacent multiomics. Its installed base and clinical-diagnostics channel are relevant comparables for Proteins.1's regulated diagnostics ambitions.
  • Thermo Fisher Scientific: Thermo Fisher's life-sciences instruments division supplies mass spectrometry, qPCR, and proteomics workflows used by the same research and clinical customers Proteins.1 targets. It also sells diagnostic instruments through its specialty diagnostics segment.

Emerging players

  • Quantum-Si: Quantum-Si is an early-stage company developing single-molecule protein sequencing using semiconductor chip technology — an alternative architectural approach to next-generation protein detection with similar ambitions to Proteins.1.

Market position

Strengths1 record

Weaknesses1 record

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Proteins.1 social profiles

Digital presence

Proteins.1 financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Proteins.1 leadership team

Management profile

Number of profiles

Profiles3 records

Proteins.1 funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Proteins.1 M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Proteins.1

What does Proteins.1 do?

Proteins.1 commercializes a physics-based, enzyme-free multiomics platform that enables ultra-sensitive single-molecule protein detection and simultaneous analysis of DNA, RNA, and proteins. The platform delivers up to 1,000 times higher detection sensitivity than current gold-standard methods, targeting research-use-only applications in oncology, neurology, and immunology with a future pathway into regulated clinical diagnostics.

Is Proteins.1 a public or private company?

Proteins.1 is a private company. It is classified as venture growth investor backed and is currently operating.

When was Proteins.1 founded?

Proteins.1 was founded in 2026. It employs 1 to 10 people.

Where is Proteins.1 based?

Proteins.1 is headquartered in Espoo, Finland, in the Europe region.

How does Proteins.1 make money?

Two revenue lines are on record. Research-Use-Only Products are the primary driver. The others are clinical Diagnostics.

Who are Proteins.1's main competitors?

Direct peers on record are Olink Holding, Quanterix, SomaLogic and Standard BioTools (formerly Fluidigm). Broad incumbents are 10x Genomics, Bio-Techne, Abcam, Illumina and Thermo Fisher Scientific. Quantum-Si is listed as an emerging player.

Does Proteins.1 have an API?

No public API is recorded for Proteins.1.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Pulse 2.0Proteins.1: Finnish Deep-Tech Startup Launches With €4.7 million to Bring PCR-Like Amplification to Protein DiagnosticsProteins.1, a VTT-originated Finnish deep-tech startup, has launched with €4.7 million in pre-seed funding to commercialize a single-molecule protein amplification technology that the company says could enable disease detection up to 1,000 times more sensitive than current gold-standard platforms. The funding round was led by Lifeline Ventures and Cloudberry Ventures, with additional in-kind support from VTT and Business Finland, and the company holds granted US and Finnish patents alongside pending international applications. Proteins.1 plans to initially target research-use-only applications in oncology, neurology, and immunology before progressing toward regulated clinical diagnostics, while expanding its engineering and product development team in Finland during 2026 and 2027.ArcticstartupFinnish Proteins.1 banks €4.7 million pre-seed to push early detection through single-molecule analysisEspoo-based Proteins.1 raised €4.7 million in pre-seed funding led by Lifeline Ventures and Cloudberry Ventures to commercialize a single-molecule protein detection platform. The physics-based, enzyme-free technology claims up to 1,000 times higher sensitivity than existing methods, targeting early disease diagnostics. The company will initially focus on research-use applications in oncology, neurology, and immunology.FinSMEsProteins.1 Raises $4.7M in Pre-Seed FundingProteins.1, a Finnish deep-tech diagnostics company, raised $4.7M in pre-seed funding led by Lifeline Ventures and Cloudberry Ventures, with participation from VTT and Business Finland. The company will use the funds to expand operations and development efforts. Its patented platform enables ultra-sensitive, high-multiplex detection of biomarkers from minimal sample volumes.GenengnewsProteins.1 Launches to Develop Single Molecule Protein Amplification Tech for DiagnosticsProteins.1, a Finnish deep-tech startup, launched with €4.7 million in pre-seed funding from Lifeline Ventures and Cloudberry Ventures, with in-kind support from VTT and Business Finland, to develop a PCR-like enzyme-free protein amplification platform for ultra-sensitive disease detection. The company's patented, physics-based technology uses cyclic signal amplification to detect proteins at the single-molecule level, claiming up to 1,000 times better sensitivity than current gold-standard diagnostic platforms. Proteins.1 plans to initially develop research-use applications in oncology, neurology, and immunology before advancing toward regulated clinical diagnostics, with team expansion targeted in Finland during 2026–2027.VTTVTT-originating startup Proteins.1 launches to bringProteins.1, a Finnish deep-tech startup spun off from VTT, has launched to commercialize a patented physics-based technology enabling ultra-sensitive single-molecule protein detection, with sensitivity up to 1,000 times higher than current gold-standard methods. The company has secured EUR 4.7 million in pre-seed funding led by Lifeline Ventures and Cloudberry VC, along with in-kind support from VTT and Business Finland, to target early disease detection in oncology, neurology, and immunology. The company plans to initially focus on research-use-only applications before advancing into regulated clinical diagnostics, with expansion of its Finnish engineering and product development team planned for 2026–2027.news.cision.comVTT-originated startup Proteins.1 launches to bring PCR-like amplification and simplicity to omicsProteins.1, a VTT-originated Finnish deep-tech startup, launched on April 16, 2026, to commercialize a physics-based single-molecule protein amplification technology enabling ultra-sensitive disease detection up to 1,000 times more sensitive than current gold-standard platforms. The company has secured €4.7 million in pre-seed funding led by Lifeline Ventures and Cloudberry Ventures, with additional in-kind support from VTT and Business Finland, and holds granted US and Finnish patents. Proteins.1 plans to initially target research-use-only applications in oncology, neurology, and immunology before progressing toward regulated clinical diagnostics, positioning itself within a global diagnostics market exceeding €100 billion annually.PR NewswireVTT-originated startup Proteins.1 launches to bring PCR-like amplification and simplicity to omicsProteins.1, a VTT-originated Finnish deep-tech startup, has launched to commercialize patented physics-based technology enabling ultra-sensitive single-molecule protein amplification for early disease detection. The company has secured €4.7 million in pre-seed funding led by Lifeline Ventures and Cloudberry Ventures, with the technology achieving detection sensitivity up to 1,000 times higher than current gold-standard platforms. Proteins.1 plans to initially focus on research-use-only applications in oncology, neurology, and immunology before advancing toward regulated clinical diagnostics, targeting the €100 billion global diagnostics market.European BiotechnologyProteins.1 launches with €4.7m to make protein detection as easy as PCRProteins.1, a Finnish deep-tech company, launched with €4.7m in pre-seed funding to enable single-molecule protein detection. Its enzyme-free, solid-state platform offers up to 1,000 times better sensitivity than current platforms, aiming to detect diseases like cancer and Alzheimer's early. The company will initially focus on research-use-only applications before moving to clinical diagnostics.BenzingaVTT-originated startup Proteins.1 launches to bring PCR-like amplification and simplicity to omicsVTT-originated Proteins.1 launched to commercialize a physics-based single-molecule protein amplification platform for ultra-sensitive biomarker detection. The company secured €4.7 million in pre-seed funding and aims for research-use-only applications in oncology, neurology, and immunology. It plans to expand its engineering team in Finland during 2026-2027.